Clinical trial
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease…
NCT00003894 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003894 |
|---|---|
| Title | Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant |
| Official title | Thalidomide vs. Placebo for Steroid Dependent or Refractory Chronic Graft vs. Host Disease (cGVHD) IND #42782 |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor |
| Intervention type | Drug |
| Interventions | thalidomide |
| Enrollment | 36 |
| Start date | Mar 1, 1999 |
| Primary completion | Jan 1, 2000 |
| Completion | Jun 1, 2002 |
| First posted | Jun 17, 2004 |
| Last update posted | Mar 7, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: